Updated on 24 July 2013
Close to 33,000 individuals and 970 exhibitors participated in the 7th in-Pharma Japan and 26th Interphex Japan, which were concurrently held from July 10-12, 2013, at Tokyo Big Sight, Japan
The 7th in-Pharma Japan and 26th Interphex Japan, both of which were held concurrently at Tokyo Big Sight, Japan, from July 10-12, 2013, concluded with much success and grandeur. The event was focused on covering the whole process of pharmaceutical R&D and manufacturing and featured technical conferences and exhibitions associated with all kinds of life science equipments, lab devices, contract services, packaging and other industry solutions.
Both in-Pharma Japan and Interphex Japan have established themselves as one of the most significant business platform where the whole Japanese pharmaceutical industry gets together and this was evident from the number of participants who took part in the joint event. While the total number of visitors were 32, 762 (including 29,358 on-site registrants, 3,378 VIP registrants and 26 special guests), the number of individuals who attended the seminars over the three days were 2,956. Moreover, a total of 196 press registrants were also seen participating in the mega event.
The exhibition, which was spread across six (East) halls and 51,380 square meters at Tokyo Big Sight convention center, showcased 970 exhibitors located in different strategic zones like the Materials Process Zone, Supplies and Transfer Zone, BioPharma Zone, Sterilizing Equipment and Clean Room Zone, Plant Engineering Zone, Water Production and Control Zone, Laboratory Measurement and Analysis Equipment Zone, Logistics Zone, IT Solutions Zone Contract Services Zone, and Process Inspection and Testing Equipment Zone.
The keynote address, which was delivered during the inauguration of the event, emphasized on how life science firms in Japan are venturing in the quest to expand to emerging markets of China, India, Brazil and Russia (BRIC) among other nations despite stifled innovation in the ‘land of the rising sun'. However, the environment in the technical sessions and at the exhibition was that of "lets innovate help Japanese life sciences get out of its stifled phase."
The keynote was delivered by Dr Taro Iwamoto, president and representative director, Otsuka Pharmaceutical, Japan; Mr Tony Alvarez, representative director and president, MSD (Merck Sharpe Dohme) KK and Mr Fumiyoshi Sakai, director, equity research, equities, Credit Suisse Securities, Japan. All three speakers concurred on the observation that in today's world, growth and innovation go hand in hand.